Expression of the tumor-rejection antigen SART1 in brain tumors

Imaizumi, T; Kuramoto, Terukazu; Matsunaga, Kazuko; Shichijo, Shigeki; Yutani, Shigeru; Shigemori, Minoru; Oizumi, K; Itoh, Kyogo

doi:10.1002/(sici)1097-0215(19991210)83:6<760::aid-ijc11>3.0.co;2-r

Cited by 51 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, T-cell epitopes derived from SART-1 and -3 (Imaizumi et al, 1999;Murayama et al, 2000), IL-13 receptor a2 chain (Okano et al, 2002), ADPribosylation factor 4-like (ARF4L) , UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) , AIM-2 (Liu et al, 2004a), EphA2 (Hatano et al, 2005) and the type III variant of the epidermal growth factor receptor (EGFRvIII) (Wu et al, 2006) have been described. In addition, it has been shown that HER-2, gp100, MAGE-1 and TRP-2 were expressed in glioma and were recognised by CTLs (Liu et al, 2003(Liu et al, , 2004b.…”

Section: Discussionmentioning

confidence: 99%

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

et al. 2007

View full text Add to dashboard Cite

Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but the number of such antigens is still very limited. SOX2 was identified by screening an expression database for transcripts that are overexpressed in malignant glioma, but display minimal expression in normal tissues. Expression of SOX2 mRNA was further investigated in tumour and normal tissues by real-time PCR. Compared to cDNA from pooled normal brain, SOX2 was overexpressed in almost all (9 out of 10) malignant glioma samples, whereas expression in other, non-malignant tissues was almost negligible. SOX2 protein expression in glioma cell lines and tumour tissues was verified by Western blot and immunofluorescence. Immunohistochemistry demonstrated SOX2 protein expression in all malignant glioma tissues investigated ranging from 6 to 66% stained tumour cells. Human leucocyte antigen-A*0201-restricted SOX2-derived peptides were tested for the activation of glioma-reactive CD8 þ cytotoxic T lymphocytes (CTLs). Specific CTLs were raised against the peptide TLMKKDKYTL and were capable of lysing glioma cells. The abundant and glioma-restricted overexpression of SOX2 and the generation of SOX2-specific and tumour-reactive CTLs may recommend this antigen as target for T-cell-based immunotherapy of glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…For brain neoplasia, this research field is far less advanced than for melanoma. A few candidates have been suggested, but their real capabilities to elicit an immune response have rarely been explored [16,17]. Considering its widespread expression pattern that we and others [12] have reported, survivin seems to be an interesting candidate to be examined.…”

Section: Discussionmentioning

confidence: 99%

Survivin in brain tumors: an attractive target for immunotherapy

et al. 2003

View full text Add to dashboard Cite

SummarySurvivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, both in vitro and in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.

show abstract

“…12, 15, 16); breast and ovarian cancers: Her2/ neu (15,16); multiple cancer types: B-cyclin (20), EphA2/Eck (21,22), telomerase reverse transcriptase (hTert; ref. 23), Sart-1 (24), survivin (25,26), and GnT-V (27). All of these antigens have elicited human immune responses, primarily in the form of CTL responses.…”

mentioning

confidence: 99%

Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics

Zhang

Eguchi

Kruse

et al. 2007

Clinical Cancer Research

130

122

View full text Add to dashboard Cite

Purpose: Allogeneic glioma cell lines that are partially matched to the patient at class I human leukocyte antigen (HLA) loci and that display tumor-associated antigens (TAA) or antigenic precursors [tumor antigen precursor proteins (TAPP)] could be used for generating whole tumor cell vaccines or, alternatively, for extraction of TAA peptides to make autologous dendritic cell vaccines. Experimental Design: Twenty human glioma cell lines were characterized by molecular phenotyping and by flow cytometry for HLA class I antigen expression. Twelve of the 20 cell lines, as well as analyses of freshly resected glioma tissues, were further characterized for protein and/or mRNA expression of 16 tumor antigen precursor proteins or TAA. Results: These 20 human glioma cell lines potentially cover 77%, 85%, and 78% of the U.S. Caucasian population at HLA-A, HLA-B, and HLA-C alleles, respectively. All cells exhibited multiple TAA expressions. Most glioma cells expressed antigen isolated from immunoselected melanoma-2 (Aim-2), B-cyclin, EphA2, GP100, h1,6-N-acetylglucosaminyltransferase V (GnT-V), IL13Ra2, Her2/neu, hTert, Mage, Mart-1, Sart-1, and survivin. Real-time PCR technology showed that glioblastoma specimens expressed most of the TAA as well. Tumor-infiltrating lymphocytes and CD8 + CTL killed T2 cells when loaded with specific HLA-A2 + restricted TAA, or gliomas that were both HLA-A2 + and also positive for specificTAA (Mart-1, GP100, Her2/neu, and tyrosinase) but not those cells negative for HLA-A2 and/or lacking the specific epitope. Conclusions: These data provide proof-in-principle for the use of allogeneic, partially HLA patient^matched glioma cells for vaccine generation or for peptide pulsing with allogeneic glioma cell extracts of autologous patient dendritic cells to induce endogenous CTL in brain tumor patients.

show abstract

Expression of the tumor-rejection antigen SART1 in brain tumors

Cited by 51 publications

References 26 publications

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Survivin in brain tumors: an attractive target for immunotherapy

Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics

Contact Info

Product

Resources

About